Schedule 1—Amendments
National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024)
[1] Schedule 1, Part 1, after entry for Abemaciclib in the form Tablet 150 mg
insert:
Abiraterone | Tablet containing abiraterone acetate 250 mg | Oral | Abiraterone Sandoz | SZ | MP | C13945 | | 120 | 2 | | 120 | | |
[2] Schedule 1, Part 1, after entry for Abiraterone in the form Tablet containing abiraterone acetate 250 mg [Brand: Zytiga]
insert:
Abiraterone | Tablet containing abiraterone acetate 500 mg | Oral | Abiraterone Sandoz | SZ | MP | C13945 | | 60 | 2 | | 60 | | |
[3] Schedule 1, Part 1, entry for Aciclovir in the form Tablet 200 mg [Brand: Aciclovir APOTEX; Maximum Quantity: 90; Number of
Repeats: 5]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[4] Schedule 1, Part 1, entry for Aciclovir in the form Tablet 200 mg [Brand: Aciclovir GH]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[5] Schedule 1, Part 1, entry for Aciclovir in the form Tablet 200 mg [Brand: Aciclovir Sandoz; Maximum Quantity: 90; Number of
Repeats: 5]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[6] Schedule 1, Part 1, entry for Aciclovir in the form Tablet 200 mg [Brand: ACICLOVIR-WGR]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[7] Schedule 1, Part 1, entry for Aciclovir in the form Tablet 200 mg [Brand: APO-Aciclovir; Maximum Quantity: 90; Number of Repeats: 5]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[8] Schedule 1, Part 1, entry for Aciclovir in the form Tablet 200 mg [Brand: ARX-Aciclovir]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[9] Schedule 1, Part 1, entries for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe
omit:
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C11713 C15473 | P11713 P15473 | 2 | 0 | | 2 | | |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C12120 C14061 C14063 C14064 C14107 C14136 | See Note 3 | See Note 3 | See Note 3 | | 2 | | C(100) |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C9715 C11709 C11715 C11716 C11759 C11761 C11852 C11854 C11855 C12098 C12101 C12147 C13602 C13609 | P9715 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P13602 P13609 | 2 | 2 | | 2 | | |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C9064 C9386 C11861 C12174 C12194 C13599 C13650 C13681 C13694 C14483 C14486 C14488 C14496 C14498 C14568 C14590 C14655 C14662 C14670 C14672 C14673 | P9064 P9386 P11861 P12174 P12194 P13599 P13650 P13681 P13694 P14483 P14486 P14488 P14496 P14498 P14568 P14590 P14655 P14662 P14670 P14672 P14673 | 2 | 3 | | 2 | | |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C11107 C12155 C12212 C13556 C13612 C14377 C14378 | P11107 P12155 P12212 P13556 P13612 P14377 P14378 | 2 | 4 | | 2 | | |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C11523 C11524 C11579 C11604 C11606 C11631 C11635 C11704 C11711 C11717 C11718 C11767 C11853 C11865 C11867 C11903 C11906 C11966 C12122 C12123 C12148 C12156 C12157 C12158 C12189 C12190 C12214 C12228 C12240 C14493 C14499 C14507 C14567 C14656 C14683 C14701 C14713 C14730 C15445 C15446 C15450 | P11523 P11524 P11579 P11604 P11606 P11631 P11635 P11704 P11711 P11717 P11718 P11767 P11853 P11865 P11867 P11903 P11906 P11966 P12122 P12123 P12148 P12156 P12157 P12158 P12189 P12190 P12214 P12228 P12240 P14493 P14499 P14507 P14567 P14656 P14683 P14701 P14713 P14730 P15445 P15446 P15450 | 2 | 5 | | 2 | | |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C15474 C15489 | P15474 P15489 | 2 | 6 | | 2 | | |
Adalimumab | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip | LR | MP | C9715 C11709 C11715 C11716 C11759 C11761 C11852 C11854 C11855 C12098 C12101 C12147 C13602 C13609 | P9715 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P13602 P13609 | 6 | 0 | | 2 | | |
[10] Schedule 1, Part 1, after entry for Amlodipine in the form Tablet 10 mg (as besilate) [Brand: APO-Amlodipine; Maximum Quantity: 60; Number of Repeats: 5]
insert:
Amlodipine | Tablet 10 mg (as besilate) | Oral | APX-AMLODIPINE | TW | MP NP | | | 30 | 5 | | 30 | | |
Amlodipine | Tablet 10 mg (as besilate) | Oral | APX-AMLODIPINE | TW | MP NP | | P14238 | 60 | 5 | | 30 | | |
[11] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL [Brand: Amoxil; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[12] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL [Brand: Amoxycillin Sandoz; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[13] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL [Brand: APO‑Amoxycillin; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[14] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL [Brand: NOUMED AMOXICILLIN; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[15] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL [Brand: AMOXICILLIN-WGR; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[16] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL [Brand: Amoxil Forte; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[17] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL [Brand: Amoxycillin Sandoz; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[18] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL [Brand: APO‑Amoxycillin; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[19] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL [Brand: Cilamox; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[20] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL [Brand: NOUMED AMOXICILLIN; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[21] Schedule 1, Part 1, entry for Amoxicillin in the form Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL [Brand: Maxamox; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[22] Schedule 1, Part 1, entries for Amoxicillin in the form Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL [Brand: Amoxil; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
[23] Schedule 1, Part 1, entry for Amoxicillin with clavulanic acid in the form Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL [Brand: Curam; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[24] Schedule 1, Part 1, entry for Amoxicillin with clavulanic acid in the form Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL [Brand: Augmentin Duo 400; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[25] Schedule 1, Part 1, entry for Amoxicillin with clavulanic acid in the form Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL [Brand: Curam Duo; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[26] Schedule 1, Part 1, entries for Amoxicillin with clavulanic acid in the form Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)
substitute:
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo | AF | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo | AF | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo | AF | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | AL | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | AL | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | AL | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO 500/125 | RW | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO 500/125 | RW | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO 500/125 | RW | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 500/125 | WG | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 500/125 | WG | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 500/125 | WG | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxycillin/Clavulanic Acid 500/125 APOTEX | TY | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxycillin/Clavulanic Acid 500/125 APOTEX | TY | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxycillin/Clavulanic Acid 500/125 APOTEX | TY | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-AMOXY/CLAV 500/125 | TW | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-AMOXY/CLAV 500/125 | TW | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-AMOXY/CLAV 500/125 | TW | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-Amoxycillin/ Clavulanic Acid 500/125 | TX | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-Amoxycillin/ Clavulanic Acid 500/125 | TX | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-Amoxycillin/ Clavulanic Acid 500/125 | TX | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APX-Amoxicillin/Clavulanic Acid | XT | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APX-Amoxicillin/Clavulanic Acid | XT | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APX-Amoxicillin/Clavulanic Acid | XT | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo | AS | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo | AS | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo | AS | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Curam Duo 500/125 | SZ | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Curam Duo 500/125 | SZ | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Curam Duo 500/125 | SZ | MP NP MW | C10405 | P10405 | 20 | 0 | | 10 | | |
[27] Schedule 1, Part 1, entries for Amoxicillin with clavulanic acid in the form Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)
substitute:
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Forte Viatris | AL | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Forte Viatris | AL | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Forte Viatris | AL | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO FORTE 875/125 | RW | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO FORTE 875/125 | RW | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO FORTE 875/125 | RW | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 875/125 | WG | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 875/125 | WG | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 875/125 | WG | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AmoxyClav generichealth 875/125 | HQ | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AmoxyClav generichealth 875/125 | HQ | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AmoxyClav generichealth 875/125 | HQ | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-AMOXY/CLAV 875/125 | TW | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-AMOXY/CLAV 875/125 | TW | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-AMOXY/CLAV 875/125 | TW | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-Amoxycillin and Clavulanic Acid | TX | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-Amoxycillin and Clavulanic Acid | TX | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APO-Amoxycillin and Clavulanic Acid | TX | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APX-Amoxicillin/Clavulanic Acid | XT | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APX-Amoxicillin/Clavulanic Acid | XT | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | APX-Amoxicillin/Clavulanic Acid | XT | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo forte | AS | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo forte | AS | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Augmentin Duo forte | AS | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Blooms The Chemist Amoxicillin/Clavulanic Acid 875/125 | BG | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Blooms The Chemist Amoxicillin/Clavulanic Acid 875/125 | BG | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Blooms The Chemist Amoxicillin/Clavulanic Acid 875/125 | BG | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Curam Duo Forte 875/125 | SZ | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Curam Duo Forte 875/125 | SZ | MP NP MW | C5832 C5893 | P5832 P5893 | 10 | 0 | | 10 | | |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Curam Duo Forte 875/125 | SZ | MP NP MW | C10413 | P10413 | 20 | 0 | | 10 | | |
[28] Schedule 1, Part 1, entry for Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: APO-Azithromycin; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[29] Schedule 1, Part 1, entry for Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: Azithromycin Sandoz; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[30] Schedule 1, Part 1, entry for Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: Azithromycin Viatris; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[31] Schedule 1, Part 1, entry for Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: AZITHROMYCIN-WGR; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[32] Schedule 1, Part 1, entry for Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: ZITHRO; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[33] Schedule 1, Part 1, entry for Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: Zithromax; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[34] Schedule 1, Part 1, entry for Benzylpenicillin in the form Powder for injection 3 g (as sodium)
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[35] Schedule 1, Part 1, entry for Cabergoline in the form Tablet 500 micrograms [Brand: Dostinex; Maximum Quantity: 2; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[36] Schedule 1, Part 1, after entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Brand: Enstilar; Maximum Quantity: 2; Number of Repeats: 1]
insert:
Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | Application | Klarvanta | LG | MP NP | C6809 | P6809 | 1 | 1 | | 1 | | |
Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | Application | Klarvanta | LG | MP NP | C14236 | P14236 | 2 | 1 | | 1 | | |
[37] Schedule 1, Part 1, entry for Cefalexin in the form Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL [Brand: Cefalexin Sandoz; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[38] Schedule 1, Part 1, entry for Cefalexin in the form Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL [Brand: Ibilex 125; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[39] Schedule 1, Part 1, entry for Cefalexin in the form Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL [Brand: Keflex; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[40] Schedule 1, Part 1, entry for Cefalexin in the form Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL [Brand: Cefalexin Sandoz; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[41] Schedule 1, Part 1, entry for Cefalexin in the form Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL [Brand: Ibilex 250; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[42] Schedule 1, Part 1, entry for Cefalexin in the form Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL [Brand: Keflex; Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[43] Schedule 1, Part 1, entries for Cefazolin
substitute:
Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin-AFT | AE | MP NP MW | C15964 | | 10 | 0 | | 5 | | |
Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin-AFT | AE | MP NP | C5883 C16029 C16030 | | 10 | 0 | | 5 | | |
Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | AL | MP NP MW | C15964 | | 10 | 0 | | 10 | | |
Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cephazolin Viatris | AL | MP NP | C5867 C16029 C16030 | | 10 | 0 | | 10 | | |
[44] Schedule 1, Part 1, entries for Ceftriaxone
substitute:
Ceftriaxone | Powder for injection 500 mg (as sodium) | Injection | Ceftriaxone-AFT | AE | MP NP MW | C5855 | P5855 | 1 | 0 | | 1 | | |
Ceftriaxone | Powder for injection 500 mg (as sodium) | Injection | Ceftriaxone-AFT | AE | MP NP MW | C15964 | P15964 | 5 | 0 | | 1 | | |
Ceftriaxone | Powder for injection 500 mg (as sodium) | Injection | Ceftriaxone-AFT | AE | MP NP | C16029 C16030 | P16029 P16030 | 5 | 0 | | 1 | | |
Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone Viatris | AL | MP NP | C16029 C16030 | | 5 | 0 | | 10 | | |
Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone Viatris | AL | MP NP MW | C15964 | | 5 | 0 | | 10 | | |
Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | AL | MP NP | C16029 C16030 | | 5 | 0 | | 5 | | |
Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | AL | MP NP MW | C15964 | | 5 | 0 | | 5 | | |
Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | AL | MP NP | C16029 C16030 | | 5 | 0 | | 10 | | |
Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | AL | MP NP MW | C15964 | | 5 | 0 | | 10 | | |
[45] Schedule 1, Part 1, entries for Codeine
omit from the column headed “Brand” (all instances): Aspen Pharma Pty Ltd substitute (all instances): Aspen Pharmacare Australia Pty Ltd
[46] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: APO- Paracetamol/Codeine 500/30; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[47] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: APX-Paracetamol/Codeine; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[48] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: Codalgin Forte; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[49] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: Codapane Forte 500/30; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[50] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: Comfarol Forte; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[51] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: Panadeine Forte; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[52] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: Paracetamol/Codeine GH 500/30; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[53] Schedule 1, Part 1, entry for Codeine with paracetamol in the form Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg [Brand: Prodeine Forte; Maximum Quantity: 10; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[54] Schedule 1, Part 1, entries for Colestyramine
omit:
Colestyramine | Powder for oral suspension 4 g (S19A) | Oral | Cholestyramine (Ascend, USA) | CR | MP NP | | | 120 | 5 | | 60 | | |
Colestyramine | Powder for oral suspension 4 g (S19A) | Oral | Cholestyramine (Ascend, USA) | CR | MP | | P6429 | 120 | 11 | | 60 | | |
[55] Schedule 1, Part 1, after entry for Dapsone in the form Tablet 25 mg
insert:
Dapsone | Tablet 100 mg | Oral | DAPSOMED | DZ | MP NP | | | 100 | 1 | | 100 | | |
[56] Schedule 1, Part 1, entry for Dexamfetamine
omit from the column headed “Brand”: Aspen Pharma Pty Ltd substitute: Aspen Pharmacare Australia Pty Ltd
[57] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg [Brand: Clonac 25; Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[58] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg [Brand: Diclofenac Sandoz; Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[59] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg [Brand: DICLOFENAC-WGR; Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[60] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg [Brand: Fenac EC; Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[61] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg [Brand: Voltaren 25; Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[62] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg [Brand: Clonac 50; Maximum Quantity: 50; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[63] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg [Brand: Diclofenac Sandoz; Maximum Quantity: 50; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[64] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg [Brand: DICLOFENAC-WGR; Maximum Quantity: 50; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[65] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg [Brand: Fenac EC; Maximum Quantity: 50; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[66] Schedule 1, Part 1, entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg [Brand: Voltaren 50; Maximum Quantity: 50; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[67] Schedule 1, Part 1, entry for Doxycycline in the form Capsule 100 mg (as hyclate) (containing enteric coated pellets) [Brand: Doryx; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[68] Schedule 1, Part 1, entry for Doxycycline in the form Capsule 100 mg (as hyclate) (containing enteric coated pellets) [Brand: Mayne Pharma Doxycycline; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[69] Schedule 1, Part 1, entry for Doxycycline in the form Tablet 100 mg (as hyclate) [Brand: APX-Doxycycline; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[70] Schedule 1, Part 1, entry for Doxycycline in the form Tablet 100 mg (as hyclate) [Brand: Doxsig; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[71] Schedule 1, Part 1, entry for Doxycycline in the form Tablet 100 mg (as hyclate) [Brand: DOXYCYCLINE-WGR; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[72] Schedule 1, Part 1, entry for Doxycycline in the form Tablet 100 mg (as hyclate) [Brand: Doxylin 100; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[73] Schedule 1, Part 1, entry for Doxycycline in the form Tablet 100 mg (as monohydrate) [Brand: Doxycycline Sandoz; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[74] Schedule 1, Part 1, entries for Enoxaparin
substitute:
Enoxaparin | Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP MW | C16261 | P16261 | 20 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Injection | Exarane | JU | MP NP MW | C16261 | P16261 | 20 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Injection | Exarane | JU | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP MW | C16261 | P16261 | 20 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Injection | Exarane | JU | MP NP MW | C16261 | P16261 | 20 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Injection | Exarane | JU | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Injection | Exarane | JU | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Injection | Exarane | JU | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Exarane | JU | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Exarane | JU | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Clexane Safety-Lock | AV | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Exarane | JU | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Exarane | JU | MP NP | C4910 | P4910 | 20 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Clexane Forte Safety-Lock | AV | MP NP MW | C16261 | | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Exarane Forte | JU | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Exarane Forte | JU | MP NP | C4910 | P4910 | 10 | 3 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Clexane Forte Safety-Lock | AV | MP NP MW | C16261 | | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Exarane Forte | JU | MP NP MW | C16261 | P16261 | 10 | 1 | | 10 | | |
Enoxaparin | Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Exarane Forte | JU | MP NP | C4910 | P4910 | 10 | 3 | | 10 | | |
[75] Schedule 1, Part 1, entry for Erythromycin in the form Capsule 250 mg (containing enteric coated pellets) [Maximum Quantity: 25; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[76] Schedule 1, Part 1, entry for Erythromycin in the form Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL [Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[77] Schedule 1, Part 1, entry for Erythromycin in the form Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL [Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[78] Schedule 1, Part 1, entry for Esomeprazole in the form Capsule (enteric) 20 mg (as magnesium) [Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[79] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: APO-Esomeprazole; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | APO-Esomeprazole | TY | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | APO-Esomeprazole | TY | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[80] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Esomeprazole GH; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole GH | GQ | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole GH | GQ | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[81] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Esomeprazole GxP; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole GxP | AF | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole GxP | AF | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[82] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Esomeprazole RBX; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole RBX | RA | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole RBX | RA | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[83] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Esomeprazole Viatris; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole Viatris | MQ | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esomeprazole Viatris | MQ | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[84] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: ESOMEPRAZOLE-WGR; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[85] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Esopreze; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esopreze | BG | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Esopreze | BG | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[86] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Nexazole; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Nexazole | RW | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Nexazole | RW | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[87] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Nexium; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Nexium | AP | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Nexium | AP | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[88] Schedule 1, Part 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium) [Brand: Nexole; Maximum Quantity: 30; Number of Repeats: 1]
substitute:
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Nexole | RF | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium) | Oral | Nexole | RF | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
[89] Schedule 1, Part 1, after entry for Estradiol in the form Transdermal patches 390 micrograms, 8
insert:
Estradiol | Transdermal patches 390 micrograms, 24 (S19A) | Transdermal | Estramon (Germany, Sandoz) | SZ | MP NP | | | 1 | 1 | | 1 | | |
[90] Schedule 1, Part 1, after entry for Estradiol in the form Transdermal patches 780 micrograms, 8
insert:
Estradiol | Transdermal patches 780 micrograms, 24 (S19A) | Transdermal | Estramon (Germany, Sandoz) | SZ | MP NP | | | 1 | 1 | | 1 | | |
[91] Schedule 1, Part 1, after entry for Estradiol in the form Transdermal patches 1.17 mg, 8 [Brand: Estradot 75]
insert:
Estradiol | Transdermal patches 1.17 mg, 24 (S19A) | Transdermal | Estramon (Germany, Sandoz) | SZ | MP NP | | | 1 | 1 | | 1 | | |
[92] Schedule 1, Part 1, after entry for Fenofibrate in the form Tablet 48 mg [Brand: Fenofibrate Cipla; Maximum Quantity: 120; Number of Repeats: 5]
insert:
Fenofibrate | Tablet 48 mg | Oral | Fenofibrate Lupin | GQ | MP NP | | | 60 | 5 | | 60 | | |
Fenofibrate | Tablet 48 mg | Oral | Fenofibrate Lupin | GQ | MP NP | | P14238 | 120 | 5 | | 60 | | |
[93] Schedule 1, Part 1, after entry for Fenofibrate in the form Tablet 145 mg [Brand: Fenofibrate Cipla; Maximum Quantity: 60; Number of Repeats: 5]
insert:
Fenofibrate | Tablet 145 mg | Oral | Fenofibrate Lupin | GQ | MP NP | | | 30 | 5 | | 30 | | |
Fenofibrate | Tablet 145 mg | Oral | Fenofibrate Lupin | GQ | MP NP | | P14238 | 60 | 5 | | 30 | | |
[94] Schedule 1, Part 1, entries for Ferric carboxymaltose
omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
[95] Schedule 1, Part 1, entry for Ferrous fumarate
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[96] Schedule 1, Part 1, entry for Ferrous fumarate with folic acid
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[97] Schedule 1, Part 1, entry for Flucloxacillin in the form Powder for injection 1 g (as sodium monohydrate) [Maximum Quantity: 5; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[98] Schedule 1, Part 1, entry for Flucloxacillin in the form Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL [Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[99] Schedule 1, Part 1, entry for Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL [Maximum Quantity: 1; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[100] Schedule 1, Part 1, entries for Folic acid
substitute:
Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 | PP | MP NP MW | C5824 | | 200 | 0 | | 100 | | |
Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | AF | MP NP MW | C5824 | | 200 | 0 | | 100 | | |
Folic acid | Tablet 5 mg | Oral | Megafol 5 | AF | MP NP MW | C5824 | | 200 | 1 | | 100 | | |
[101] Schedule 1, Part 1, entries for Ganirelix
substitute:
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | ARX Ganirelix | XT | MP | C5046 | | 10 | 0 | | 1 | | D(100) |
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | ARX Ganirelix | XT | MP | C5046 | | 10 | 0 | | 5 | | D(100) |
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | GANIRELIX SUN | RA | MP | C5046 | | 10 | 0 | | 1 | | D(100) |
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | GANIRELIX SUN | RA | MP | C5046 | | 10 | 0 | | 5 | | D(100) |
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | Ganirelix Theramex | TT | MP | C5046 | | 10 | 0 | | 5 | | D(100) |
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | Orgalutran | OQ | MP | C5046 | | 10 | 0 | | 1 | | D(100) |
Ganirelix | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | Orgalutran | OQ | MP | C5046 | | 10 | 0 | | 5 | | D(100) |
[102] Schedule 1, Part 1, entry for Gentamicin
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[103] Schedule 1, Part 1, entries for Hydroxocobalamin
substitute:
Hydroxocobalamin | Injection 1 mg (as acetate) in 1 mL | Injection | Cobal-B12 | JU | MP NP MW | C16269 C16288 C16289 | | 3 | 0 | | 3 | | |
Hydroxocobalamin | Injection 1 mg (as acetate) in 1 mL | Injection | Vita-B12 | GH | MP NP MW | C16269 C16288 C16289 | | 3 | 0 | | 3 | | |
Hydroxocobalamin | Injection 1 mg (as chloride) in 1 mL | Injection | Hydroxo-B12 | AS | MP NP MW | C16269 C16288 C16289 | | 3 | 0 | | 3 | | |
Hydroxocobalamin | Injection 1 mg (as chloride) in 1 mL | Injection | Neo-B12 | PF | MP NP MW | C16269 C16288 C16289 | | 3 | 0 | | 3 | | |
[104] Schedule 1, Part 1, entry for Indometacin in the form Suppository 100 mg [Maximum Quantity: 40; Number of Repeats: 3]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[105] Schedule 1, Part 1, entry for Iron polymaltose complex [Maximum Quantity: 5; Number of Repeats: 0]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[106] Schedule 1, Part 1, entry for Labetalol [Maximum Quantity: 100; Number of Repeats: 5]
(a) omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
(b) insert in the column headed “Circumstances”: C16261
(c) insert in the column headed “Purposes”: P16261
[107] Schedule 1, Part 1, entry for Labetalol [Maximum Quantity: 200; Number of Repeats: 5]
insert in the column headed “Circumstances”: C14238
[108] Schedule 1, Part 1, entry for Levonorgestrel in the form Intrauterine drug delivery system 19.5 mg
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[109] Schedule 1, Part 1, entry for Levonorgestrel in the form Intrauterine drug delivery system 52 mg
substitute:
Levonorgestrel | Intrauterine drug delivery system 52 mg | Intrauterine | Mirena | BN | MP NP MW | C5214 | | 1 | 0 | | 1 | | |
Levonorgestrel | Intrauterine drug delivery system 52 mg | Intrauterine | Mirena | BN | MP NP | C5135 C5289 | | 1 | 0 | | 1 | | |
[110] Schedule 1, Part 1, entry for Levothyroxine in the form Tablet containing 50 micrograms anhydrous levothyroxine sodium
(a) omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
(b) insert in the column headed “Circumstances” (all instances): C16261
[111] Schedule 1, Part 1, entries for Levothyroxine in the form Tablet containing 75 micrograms anhydrous levothyroxine sodium
(a) omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
(b) insert in the column headed “Circumstances” (all instances): C16261
[112] Schedule 1, Part 1, entries for Levothyroxine in the form Tablet containing 100 micrograms anhydrous levothyroxine sodium
(a) omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
(b) insert in the column headed “Circumstances” (all instances): C16261
[113] Schedule 1, Part 1, entry for Levothyroxine in the form Tablet containing 125 micrograms anhydrous levothyroxine sodium
(a) omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
(b) insert in the column headed “Circumstances”: C16261
[114] Schedule 1, Part 1, entries for Levothyroxine in the form Tablet containing 200 micrograms anhydrous levothyroxine sodium
(a) omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
(b) insert in the column headed “Circumstances” (all instances): C16261
[115] Schedule 1, Part 1, entry for Lidocaine in the form Injection containing lidocaine hydrochloride monohydrate 50 mg in 5 mL
omit from the column headed “Section 100/ Prescriber Bag only”: PB(MP) PB(NP) substitute: PB(MP) PB(NP) PB(MW)
[116] Schedule 1, Part 1, after entry for Maraviroc in the form Tablet 150 mg
insert:
Maraviroc | Tablet 150 mg | Oral | Maraviroc Waymade | IX | MP NP | C5008 | | 120 | 5 | | 60 | | D(100) |
[117] Schedule 1, Part 1, after entry for Maraviroc in the form Tablet 300 mg
insert:
Maraviroc | Tablet 300 mg | Oral | Maraviroc Waymade | IX | MP NP | C5008 | | 120 | 5 | | 60 | | D(100) |
[118] Schedule 1, Part 1, entry for Medroxyprogesterone in the form Injection containing medroxyprogesterone acetate 150 mg in 1 mL pre-filled syringe
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[119] Schedule 1, Part 1, entries for Metformin
substitute:
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | APO-Metformin XR 500 | TX | MP NP MW | C16261 | P16261 | 120 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | APO-Metformin XR 500 | TX | MP NP | C14238 | P14238 | 240 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Diabex XR 500 | AL | MP NP MW | C16261 | P16261 | 120 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Diabex XR 500 | AL | MP NP | C14238 | P14238 | 240 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Diaformin Alphapharm XR | MQ | MP NP MW | C16261 | P16261 | 120 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Diaformin Alphapharm XR | MQ | MP NP | C14238 | P14238 | 240 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Metex XR | RW | MP NP MW | C16261 | P16261 | 120 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Metex XR | RW | MP NP | C14238 | P14238 | 240 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR XR | WG | MP NP MW | C16261 | P16261 | 120 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR XR | WG | MP NP | C14238 | P14238 | 240 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Pharmacor Metformin XR | CR | MP NP MW | C16261 | P16261 | 120 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Pharmacor Metformin XR | CR | MP NP | C14238 | P14238 | 240 | 5 | | 120 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | APO-Metformin XR 1000 | TX | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | APO-Metformin XR 1000 | TX | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diabex XR 1000 | AL | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diabex XR 1000 | AL | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diaformin Alphapharm XR | MQ | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diaformin Alphapharm XR | MQ | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diaformin XR 1000 | AF | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Diaformin XR 1000 | AF | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | METEX XR | RF | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | METEX XR | RF | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | METFORMIN-WGR XR | WG | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | METFORMIN-WGR XR | WG | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Pharmacor Metformin XR | CR | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Pharmacor Metformin XR | CR | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | APX-METFORMIN | TY | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | APX-METFORMIN | TY | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Blooms The Chemist Metformin 500 mg | BG | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Blooms The Chemist Metformin 500 mg | BG | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diabex | AL | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diabex | AL | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diaformin | AF | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diaformin | AF | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diaformin Viatris | MQ | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Diaformin Viatris | MQ | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | FORMET 500 | RF | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | FORMET 500 | RF | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Glucobete 500 | ZS | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Glucobete 500 | ZS | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Metformin GH | HQ | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Metformin GH | HQ | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Metformin Sandoz | SZ | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Metformin Sandoz | SZ | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR | WG | MP NP MW | C16261 | P16261 | 100 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR | WG | MP NP | C14238 | P14238 | 200 | 5 | | 100 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | APX-METFORMIN | TY | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | APX-METFORMIN | TY | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Blooms The Chemist Metformin 850 mg | BG | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Blooms The Chemist Metformin 850 mg | BG | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diabex 850 | AL | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diabex 850 | AL | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diaformin 850 | AF | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diaformin 850 | AF | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diaformin Viatris | MQ | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diaformin Viatris | MQ | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | FORMET 850 | RF | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | FORMET 850 | RF | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Glucobete 850 | ZS | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Glucobete 850 | ZS | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Metformin Sandoz | SZ | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Metformin Sandoz | SZ | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | METFORMIN-WGR | WG | MP NP MW | C16261 | P16261 | 60 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | METFORMIN-WGR | WG | MP NP | C14238 | P14238 | 120 | 5 | | 60 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | APX-METFORMIN | TY | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | APX-METFORMIN | TY | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Blooms The Chemist Metformin 1000 mg | BG | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Blooms The Chemist Metformin 1000 mg | BG | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diabex 1000 | AL | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diabex 1000 | AL | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diaformin 1000 | AF | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diaformin 1000 | AF | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diaformin Viatris | MQ | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diaformin Viatris | MQ | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Formet 1000 | RW | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Formet 1000 | RW | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Glucobete 1000 | ZS | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Glucobete 1000 | ZS | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Metformin GH | HQ | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Metformin GH | HQ | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Metformin Sandoz | SZ | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Metformin Sandoz | SZ | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | METFORMIN-WGR | WG | MP NP MW | C16261 | P16261 | 90 | 5 | | 90 | | |
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | METFORMIN-WGR | WG | MP NP | C14238 | P14238 | 180 | 5 | | 90 | | |
[120] Schedule 1, Part 1, after entry for Methotrexate in the form Tablet 10 mg [Brand: ARX-Methotrexate; Maximum Quantity: 50; Number of Repeats: 2]
insert:
Methotrexate | Tablet 10 mg | Oral | Chexate | OX | MP NP | | | 10 | 5 | | 10 | | |
[121] Schedule 1, Part 1, entries for Methyldopa
(a) omit from the column headed “Authorised Prescriber” (all instances): MP NP substitute (all instances): MP NP MW
(b) omit from the column headed “Circumstances” (all instances): C13887 substitute (all instances): C16273
[122] Schedule 1, Part 1, entries for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 18 mg (extended release)
omit from the column headed “Circumstances” (all instances): C16189 substitute (all instances): C16274
[123] Schedule 1, Part 1, entries for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 27 mg (extended release)
omit from the column headed “Circumstances” (all instances): C16189 substitute (all instances): C16274
[124] Schedule 1, Part 1, entries for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 36 mg (extended release)
omit from the column headed “Circumstances” (all instances): C16189 substitute (all instances): C16274
[125] Schedule 1, Part 1, entries for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 54 mg (extended release)
omit from the column headed “Circumstances” (all instances): C16189 substitute (all instances): C16274
[126] Schedule 1, Part 1, entry for Metronidazole in the form Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL
omit from the column headed “Authorised Prescriber”: MP NP PDP substitute: MP NP MW PDP
[127] Schedule 1, Part 1, entry for Metronidazole in the form Tablet 200 mg [Brand: Metrogyl 200; Maximum Quantity: 21; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[128] Schedule 1, Part 1, entry for Metronidazole in the form Tablet 200 mg [Brand: METRONIDAMED; Maximum Quantity: 21; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[129] Schedule 1, Part 1, entry for Metronidazole in the form Tablet 400 mg [Brand: Flagyl; Maximum Quantity: 21; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[130] Schedule 1, Part 1, entry for Metronidazole in the form Tablet 400 mg [Brand: Metrogyl 400; Maximum Quantity: 21; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[131] Schedule 1, Part 1, entry for Metronidazole in the form Tablet 400 mg [Brand: METRONIDAMED; Maximum Quantity: 21; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[132] Schedule 1, Part 1, entries for Mirtazapine in the form Tablet 45 mg
omit:
Mirtazapine | Tablet 45 mg | Oral | NOUMED MIRTAZAPINE | VO | MP NP | C5650 | P5650 | 30 | 5 | | 30 | | |
Mirtazapine | Tablet 45 mg | Oral | NOUMED MIRTAZAPINE | VO | MP NP | C15553 | P15553 | 60 | 2 | | 30 | | |
[133] Schedule 1, Part 1, entries for Naloxone
substitute:
Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | Naloxone Hydrochloride (DBL) | PF | MP NP MW PDP | | | 5 | 0 | | 5 | | |
Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | Naloxone Juno | JU | MP NP MW PDP | | | 5 | 0 | | 5 | | |
Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | NALOXONE SXP | XN | MP NP MW PDP | | | 5 | 0 | | 5 | | |
Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | NARCAN | FF | See Note 4 | See Note 4 | See Note 4 | See Note 4 | See Note 4 | | 10 | 10 | PB(MP) PB(NP) PB(MW) |
Naloxone | Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe | Injection | Prenoxad | FF | MP NP MW PDP | | | 1 | 0 | | 1 | | |
Naloxone | Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 | Nasal | Nyxoid | MF | MP NP MW PDP | | | 1 | 0 | | 1 | | |
[134] Schedule 1, Part 1, entry for Norethisterone in the form Tablets 350 micrograms, 28
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[135] Schedule 1, Part 1, entries for Omeprazole
substitute:
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | OMEPRAZOLE CAPS WGR | WG | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | OMEPRAZOLE CAPS WGR | WG | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | OMEPRAZOLE CAPS WGR | WG | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | OMEPRAZOLE CAPS WGR | WG | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | OMEPRAZOLE CAPS WGR | WG | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | OMEPRAZOLE CAPS WGR | WG | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 10 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP MW | C5444 | P5444 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 10 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C5512 C5529 | P5512 P5529 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 10 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP MW | C8774 | P8774 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP | C8775 | P8775 | 30 | 1 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP | C11310 | P11310 | 60 | 5 | | 30 | | |
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP | C15856 | P15856 | 120 | 5 | | 30 | | |
[136] Schedule 1, Part 1, entries for Oxycodone in the form Capsule containing oxycodone hydrochloride 5 mg
substitute:
Oxycodone | Capsule containing oxycodone hydrochloride 5 mg | Oral | Oxycodone BNM | BZ | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Oxycodone | Capsule containing oxycodone hydrochloride 5 mg | Oral | Oxycodone BNM | BZ | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Oxycodone | Capsule containing oxycodone hydrochloride 5 mg | Oral | OxyNorm | MF | MP NP MW | C16276 | P16276 | 10 | 0 | | 10 | | |
Oxycodone | Capsule containing oxycodone hydrochloride 5 mg | Oral | OxyNorm | MF | PDP | C10766 | P10766 | 10 | 0 | | 10 | | |
Oxycodone | Capsule containing oxycodone hydrochloride 5 mg | Oral | OxyNorm | MF | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Oxycodone | Capsule containing oxycodone hydrochloride 5 mg | Oral | OxyNorm | MF | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
[137] Schedule 1, Part 1, entries for Oxycodone in the form Tablet containing oxycodone hydrochloride 5 mg
substitute:
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | ENDONE | AF | MP NP MW | C16276 | P16276 | 10 | 0 | | 10 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | ENDONE | AF | PDP | C10766 | P10766 | 10 | 0 | | 10 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | ENDONE | AF | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | ENDONE | AF | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Mayne Pharma Oxycodone IR | SZ | MP NP | C10764 C10771 C10772 | | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Mayne Pharma Oxycodone IR | SZ | PDP | C10768 | | 20 | 0 | | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | MQ | MP NP MW | C16276 | P16276 | 10 | 0 | | 10 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | MQ | PDP | C10766 | P10766 | 10 | 0 | | 10 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | MQ | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | MQ | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxyndone | TX | MP NP | C10764 C10771 C10772 | | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxyndone | TX | PDP | C10768 | | 20 | 0 | | 20 | | |
[138] Schedule 1, Part 1, entries for Paclitaxel, nanoparticle albumin-bound
substitute:
Paclitaxel, nanoparticle albumin-bound | Powder for I.V. injection containing 100 mg paclitaxel | Injection | Abraxane | TS | MP | C4657 C6106 C6119 | | See Note 3 | See Note 3 | | 1 | | D(100 |
Paclitaxel, nanoparticle albumin-bound | Powder for I.V. injection containing 100 mg paclitaxel | Injection | nab-PACLITAXEL JUNO | JU | MP | C4657 C6106 C6119 | | See Note 3 | See Note 3 | | 1 | | D(100) |
[139] Schedule 1, Part 1, entries for Pembrolizumab
substitute:
Pembrolizumab | Solution concentrate for I.V. infusion 100 mg in 4 mL | Injection | Keytruda | MK | MP | C10676 C10688 C10701 C10705 C13432 C13437 C13726 C13727 C13728 C13730 C13731 C13732 C13735 C13736 C13739 C13741 C13948 C13949 C14027 C14044 C14324 C14403 C14404 C14727 C14770 C14786 C14817 C14818 C16264 C16280 | | See Note 3 | See Note 3 | | 1 | | D(100) |
[140] Schedule 1, Part 1, after entry for Pirfenidone in the form Tablet 801mg [Brand: Pirfenidone Sandoz]
insert:
Pirfenidone | Tablet 267 mg | Oral | ARX-Pirfenidone | XW | MP | C13378 C13380 C13381 | | 270 | 5 | | 90 | | |
[141] Schedule 1, Part 1, entries for Prochlorperazine
omit from the column headed “Authorised Prescriber” (all instances): MP NP PDP substitute (all instances): MP NP MW PDP
[142] Schedule 1, Part 1, entries for Promethazine
substitute:
Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | Injection | DBL Promethazine Hydrochloride | PF | MP NP MW PDP | | | 10 | 0 | | 5 | | |
[143] Schedule 1, Part 1, after entry for Rivaroxaban in the form Tablet 2.5 mg [Brand: Xarelto; Maximum Quantity: 120; Number of Repeats: 5]
insert:
Rivaroxaban | Tablet 10 mg | Oral | ARX-Rivaroxaban 10 | XT | MP NP | C4382 | P4382 | 15 | 0 | | 15 | | |
Rivaroxaban | Tablet 10 mg | Oral | ARX-Rivaroxaban 10 | XT | MP NP | C4402 | P4402 | 15 | 1 | | 15 | | |
Rivaroxaban | Tablet 10 mg | Oral | ARX-Rivaroxaban 10 | XT | MP NP | C4402 | P4402 | 30 | 0 | | 30 | | |
Rivaroxaban | Tablet 10 mg | Oral | ARX-Rivaroxaban 10 | XT | MP NP | C4132 | P4132 | 30 | 5 | | 30 | | |
Rivaroxaban | Tablet 10 mg | Oral | ARX-Rivaroxaban 10 | XT | MP NP | C14300 | P14300 | 60 | 5 | | 30 | | |
[144] Schedule 1, Part 1, after entry for Rivaroxaban in the form Tablet 10 mg [Brand: iXarola; Maximum Quantity: 60; Number of Repeats: 5]
insert:
Rivaroxaban | Tablet 10 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C4402 | P4402 | 30 | 0 | | 30 | | |
Rivaroxaban | Tablet 10 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C4132 | P4132 | 30 | 5 | | 30 | | |
Rivaroxaban | Tablet 10 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C14300 | P14300 | 60 | 5 | | 30 | | |
[145] Schedule 1, Part 1, after entry for Rivaroxaban in the form Tablet 10 mg [Brand: Xarelto; Maximum Quantity: 60; Number of Repeats: 5]
insert:
Rivaroxaban | Tablet 15 mg | Oral | ARX-Rivaroxaban 15 | XT | MP NP | C4269 | P4269 | 28 | 5 | | 28 | | |
Rivaroxaban | Tablet 15 mg | Oral | ARX-Rivaroxaban 15 | XT | MP NP | C4098 C5098 | P4098 P5098 | 42 | 0 | | 42 | | |
Rivaroxaban | Tablet 15 mg | Oral | ARX-Rivaroxaban 15 | XT | MP NP | C14301 | P14301 | 56 | 5 | | 28 | | |
[146] Schedule 1, Part 1, after entry for Rivaroxaban in the form Tablet 15 mg [Brand: iXarola; Maximum Quantity: 56; Number of Repeats: 5]
insert:
Rivaroxaban | Tablet 15 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C4269 | P4269 | 28 | 5 | | 28 | | |
Rivaroxaban | Tablet 15 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C14301 | P14301 | 56 | 5 | | 28 | | |
[147] Schedule 1, Part 1, after entry for Rivaroxaban in the form Tablet 15 mg [Brand: Xarelto; Maximum Quantity: 56; Number of Repeats: 5]
insert:
Rivaroxaban | Tablet 20 mg | Oral | ARX-Rivaroxaban 20 | XT | MP NP | C4099 C4132 C4268 C4269 | P4099 P4132 P4268 P4269 | 28 | 5 | | 28 | | |
Rivaroxaban | Tablet 20 mg | Oral | ARX-Rivaroxaban 20 | XT | MP NP | C14264 C14300 C14301 C14318 | P14264 P14300 P14301 P14318 | 56 | 5 | | 28 | | |
[148] Schedule 1, Part 1, after entry for Rivaroxaban in the form Tablet 20 mg [Brand: iXarola; Maximum Quantity: 56; Number of Repeats: 5]
insert:
Rivaroxaban | Tablet 20 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C4099 C4132 C4268 C4269 | P4099 P4132 P4268 P4269 | 28 | 5 | | 28 | | |
Rivaroxaban | Tablet 20 mg | Oral | Rivaroxaban Dr.Reddy's | RZ | MP NP | C14264 C14300 C14301 C14318 | P14264 P14300 P14301 P14318 | 56 | 5 | | 28 | | |
[149] Schedule 1, Part 1, entry for Saxagliptin with dapagliflozin in the form Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C15269 substitute: C16290
(b) omit from the column headed “Purposes”: P15269 substitute: P16290
[150] Schedule 1, Part 1, entry for Saxagliptin with dapagliflozin in the form Tablet containing saxagliptin 5 mg with dapaglifozin 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C15270 substitute: C16285
(b) omit from the column headed “Purposes”: P15270 substitute: P16285
[151] Schedule 1, Part 1, after entry for Selinexor in the form Tablet 20 mg [Maximum Quantity: 32; Number of Repeats: 2]
insert:
Selpercatinib | Capsule 40 mg | Oral | Retevmo | LY | MP | C16270 | | 56 | 5 | | 56 | | |
Selpercatinib | Capsule 80 mg | Oral | Retevmo | LY | MP | C16282 | | 112 | 5 | | 56 | | |
[152] Schedule 1, Part 1, entries for Sunitinib
substitute:
Sunitinib | Capsule 12.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sutent | PF | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sutent | PF | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sutent | PF | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 12.5 mg | Oral | Sutent | PF | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | ARX-Sunitinib | XT | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | ARX-Sunitinib | XT | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | ARX-Sunitinib | XT | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | ARX-Sunitinib | XT | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sunitinib Sandoz | SZ | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sunitinib Sandoz | SZ | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sunitinib Sandoz | SZ | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sunitinib Sandoz | SZ | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sutent | PF | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sutent | PF | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sutent | PF | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 25 mg | Oral | Sutent | PF | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | ARX-Sunitinib | XT | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | ARX-Sunitinib | XT | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | ARX-Sunitinib | XT | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | ARX-Sunitinib | XT | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sunitinib Sandoz | SZ | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sutent | PF | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sutent | PF | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sutent | PF | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 37.5 mg | Oral | Sutent | PF | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | ARX-Sunitinib | XT | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | ARX-Sunitinib | XT | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | ARX-Sunitinib | XT | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | ARX-Sunitinib | XT | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sunitinib Sandoz | SZ | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sunitinib Sandoz | SZ | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sunitinib Sandoz | SZ | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sunitinib Sandoz | SZ | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sutent | PF | MP | C11878 C13152 C13153 | P11878 P13152 P13153 | 28 | 1 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sutent | PF | MP | C4862 | P4862 | 28 | 2 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sutent | PF | MP | C11875 | P11875 | 28 | 3 | | 28 | | |
Sunitinib | Capsule 50 mg | Oral | Sutent | PF | MP | C7471 | P7471 | 28 | 5 | | 28 | | |
[153] Schedule 1, Part 1, entries for Telmisartan in the form Tablet 40 mg
omit:
Telmisartan | Tablet 40 mg | Oral | NOUMED TELMISARTAN | VO | MP NP | | | 28 | 5 | | 28 | | |
Telmisartan | Tablet 40 mg | Oral | NOUMED TELMISARTAN | VO | MP NP | | P14238 | 56 | 5 | | 28 | | |
[154] Schedule 1, Part 1, entries for Temazepam
substitute:
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | PDP | | | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | MP NP MW | | P16279 | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | MP NP | | P6175 | 50 CN6175 | 3 CN6175 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | MP NP | | P5661 P5941 P5950 | 50 CN5661 CN5941 CN5950 | 5 CN5661 CN5941 CN5950 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Normison | AS | PDP | | | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Normison | AS | MP NP MW | | P16279 | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Normison | AS | MP NP | | P6175 | 50 CN6175 | 3 CN6175 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Normison | AS | MP NP | | P5661 P5941 P5950 | 50 CN5661 CN5941 CN5950 | 5 CN5661 CN5941 CN5950 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temaze | AF | PDP | | | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temaze | AF | MP NP MW | | P16279 | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temaze | AF | MP NP | | P6175 | 50 CN6175 | 3 CN6175 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temaze | AF | MP NP | | P5661 P5941 P5950 | 50 CN5661 CN5941 CN5950 | 5 CN5661 CN5941 CN5950 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | PDP | | | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | MP NP MW | | P16279 | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | MP NP | | P6175 | 50 CN6175 | 3 CN6175 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | MP NP | | P5661 P5941 P5950 | 50 CN5661 CN5941 CN5950 | 5 CN5661 CN5941 CN5950 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | PDP | | | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | MP NP MW | | P16279 | 25 | 0 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | MP NP | | P6175 | 50 CN6175 | 3 CN6175 | | 25 | | |
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | MP NP | | P5661 P5941 P5950 | 50 CN5661 CN5941 CN5950 | 5 CN5661 CN5941 CN5950 | | 25 | | |
[155] Schedule 1, Part 1, entries for Tenofovir in the form Tablet containing tenofovir disoproxil maleate 300 mg
omit:
Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Mylan | AF | MP NP | C10362 | P10362 | 60 | 2 | | 30 | | D(100) |
Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Mylan | AF | MP NP | C6980 C6982 C6983 C6984 C6992 C6998 | P6980 P6982 P6983 P6984 P6992 P6998 | 60 | 5 | | 30 | | D(100) |
[156] Schedule 1, Part 1, after entry for Tiagabine in the form Tablet 15 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]
insert:
Ticagrelor | Tablet 90 mg | Oral | ARX-TICAGRELOR | XT | MP NP | C5746 | P5746 | 56 | 5 | | 56 | | |
Ticagrelor | Tablet 90 mg | Oral | ARX-TICAGRELOR | XT | MP NP | C14240 | P14240 | 112 | 5 | | 56 | | |
[157] Schedule 1, Part 1, after entry for Ticagrelor in the form Tablet 90 mg [Brand: Brilinta; Maximum Quantity: 112; Number of Repeats: 5]
insert:
Ticagrelor | Tablet 90 mg | Oral | TICALOR | XE | MP NP | C5746 | P5746 | 56 | 5 | | 56 | | |
Ticagrelor | Tablet 90 mg | Oral | TICALOR | XE | MP NP | C14240 | P14240 | 112 | 5 | | 56 | | |
[158] Schedule 1, Part 1, entries for Tramadol in the form Capsule containing tramadol hydrochloride 50 mg
substitute:
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | MP NP MW | C16276 | P16276 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | PDP | C10766 | P10766 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | MP NP MW | C16276 | P16276 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | PDP | C10766 | P10766 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | MP NP MW | C16276 | P16276 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | PDP | C10766 | P10766 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | MP NP MW | C16276 | P16276 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | PDP | C10766 | P10766 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | MP NP MW | C16276 | P16276 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | PDP | C10766 | P10766 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | MP NP MW | C16276 | P16276 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | PDP | C10766 | P10766 | 10 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | PDP | C10768 | P10768 | 20 | 0 | | 20 | | |
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 | | |
[159] Schedule 1, Part 1, entry for Trimethoprim in the form Tablet 300 mg [Brand: Alprim; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[160] Schedule 1, Part 1, entry for Trimethoprim in the form Tablet 300 mg [Brand: Trimethoprim Viatris; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[161] Schedule 1, Part 1, entry for Trimethoprim in the form Tablet 300 mg [Brand: TRIMETHOPRIM-WGR; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[162] Schedule 1, Part 1, entry for Trimethoprim in the form Tablet 300 mg [Brand: Triprim; Maximum Quantity: 7; Number of Repeats: 1]
omit from the column headed “Authorised Prescriber”: MP NP substitute: MP NP MW
[163] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: APX-Valaciclovir; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | APX-Valaciclovir | TY | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | APX-Valaciclovir | TY | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[164] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Shilova 500]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Shilova 500 | ZS | MP NP MW | C5940 | | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Shilova 500 | ZS | MP NP | C5961 | | 30 | 5 | | 30 | | |
[165] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Vaclovir; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Vaclovir | AF | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Vaclovir | AF | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[166] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Valaciclovir APOTEX; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir APOTEX | GX | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir APOTEX | GX | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[167] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Valaciclovir RBX; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir RBX | RA | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir RBX | RA | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[168] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Valaciclovir Sandoz; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir Sandoz | SZ | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir Sandoz | SZ | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[169] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Valaciclovir SZ]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir SZ | HX | MP NP MW | C5940 | | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir SZ | HX | MP NP | C5961 | | 30 | 5 | | 30 | | |
[170] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: VALACICLOVIR-WGR; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | VALACICLOVIR-WGR | WG | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | VALACICLOVIR-WGR | WG | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[171] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Valtrex; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valtrex | RW | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valtrex | RW | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[172] Schedule 1, Part 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Brand: Zelitrex; Maximum Quantity: 30; Number of Repeats: 5]
substitute:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Zelitrex | RF | MP NP MW | C5940 | P5940 | 30 | 5 | | 30 | | |
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Zelitrex | RF | MP NP | C5961 | P5961 | 30 | 5 | | 30 | | |
[173] Schedule 1, Part 1, entry for Vancomycin in the form Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) [Maximum Quantity: 5; Number of Repeats: 0]
substitute:
Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | AL | MP MW | C5769 | P5769 | 5 | 0 | | 1 | | |
Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | AL | MP | C5716 | P5716 | 5 | 0 | | 1 | | |
[174] Schedule 1, Part 1, entry for Vancomycin in the form Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) [Maximum Quantity: 3; Number of Repeats: 0]
substitute:
Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | AL | MP MW | C5769 | P5769 | 3 | 0 | | 1 | | |
Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | AL | MP | C5716 | P5716 | 3 | 0 | | 1 | | |
[175] Schedule 1, Part 2, omit entries for Alirocumab
[176] Schedule 1, Part 2, omit entry for Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides
[177] Schedule 1, Part 2, omit entries for Carmellose
[178] Schedule 1, Part 2, omit entry for Carmellose with glycerin
[179] Schedule 1, Part 2, omit entry for Glucose indicator-urine
[180] Schedule 1, Part 2, omit entries for Niraparib
[181] Schedule 3,
omit table and substitute:
Code | Responsible Person | ABN |
AB | Abbott Australasia Pty Ltd | 95 000 180 389 |
AE | AFT Pharmaceuticals (AU) Pty Ltd | 29 105 636 413 |
AF | Alphapharm Pty Ltd | 93 002 359 739 |
AL | Alphapharm Pty Ltd | 93 002 359 739 |
AN | Amgen Australia Pty Limited | 31 051 057 428 |
AP | AstraZeneca Pty Ltd | 54 009 682 311 |
AQ | Alcon Laboratories (Australia) Pty Ltd | 88 000 740 830 |
AS | Aspen Pharmacare Australia Pty Limited | 51 096 236 985 |
AV | sanofi-aventis Australia Pty Ltd | 31 008 558 807 |
BB | Blackmores Limited | 35 009 713 437 |
BD | Biogen Australia Pty Ltd | 30 095 760 115 |
BG | Sandoz Pty Ltd | 60 075 449 553 |
BN | Bayer Australia Ltd | 22 000 138 714 |
BQ | Bristol-Myers Squibb Australia Pty Ltd | 33 004 333 322 |
BX | BAXTER HEALTHCARE PTY LTD | 43 000 392 781 |
BY | Boehringer Ingelheim Pty Ltd | 52 000 452 308 |
BZ | Boucher & Muir Pty Ltd | 58 000 140 474 |
CF | CNS Pharma Pty Ltd | 76 121 515 400 |
CR | Pharmacor Pty Limited | 58 121 020 835 |
CS | Seqirus (Australia) Pty Ltd | 66 120 398 067 |
CX | Contact Lens Centre Australia Limited | 42 092 190 040 |
DE | Stallergenes Australia Pty Ltd | 17 151 366 540 |
DV | Medical Developments International Limited | 14 106 340 667 |
DX | Ascensia Diabetes Care Australia Pty Limited | 62 607 554 325 |
DZ | Medsurge Healthcare Pty Ltd | 92 124 728 892 |
EI | Eisai Australia Pty Ltd | 73 117 970 993 |
EJ | Encapsulate Pharma Pty Ltd | 80 640 718 289 |
EO | Ego Pharmaceuticals Pty Ltd | 86 005 142 361 |
EU | Chiesi Australia Pty Ltd | 72 145 180 865 |
EV | Teva Pharma Australia Pty Ltd | 41 169 715 664 |
EW | Celltrion Healthcare Australia Pty Ltd | 66 625 407 105 |
FB | Pierre Fabre Australia Pty Ltd | 30 098 999 850 |
FD | Dr Falk Pharma Australia Pty Ltd | 40 631 091 131 |
FF | Phebra Pty Ltd | 99 059 357 890 |
FG | Phebra Pty Ltd | 99 059 357 890 |
FI | Boehringer Ingelheim Pty Ltd | 52 000 452 308 |
FJ | Pharmaco (Australia) Limited | 89 113 383 501 |
FK | A.Menarini Australia Pty Limited | 62 116 935 758 |
FP | Ferring Pharmaceuticals Pty Limited | 87 003 037 170 |
FQ | Pharmaco (Australia) Limited | 89 113 383 501 |
FT | AMICUS THERAPEUTICS PTY LTD | 87 621 776 476 |
FX | Gedeon Richter Australia Pty Ltd | 98 602 550 274 |
FZ | Pfizer Australia Pty Ltd | 50 008 422 348 |
GA | Galderma Australia Pty Ltd | 12 003 976 930 |
GC | GlaxoSmithKline Australia Pty Ltd | 47 100 162 481 |
GH | Amdipharm Mercury (Australia) Pty Limited | 91 118 106 684 |
GI | Gilead Sciences Pty Limited | 71 072 611 708 |
GJ | HALEON AUSTRALIA PTY LTD | 68 603 310 292 |
GK | GlaxoSmithKline Australia Pty Ltd | 47 100 162 481 |
GO | Viatris Pty Ltd | 29 601 608 771 |
GQ | Generic Health Pty Ltd | 93 110 617 859 |
GT | Viatris Pty Ltd | 29 601 608 771 |
GX | Apotex Pty Ltd | 52 096 916 148 |
GZ | sanofi-aventis Australia Pty Ltd | 31 008 558 807 |
HB | Besins Healthcare Australia Pty Ltd | 68 164 882 062 |
HQ | Generic Health Pty Ltd | 93 110 617 859 |
HT | BTC Speciality Health Pty Ltd | 28 621 706 929 |
HW | HAMELN PHARMA PTY. LTD. | 69 638 348 580 |
HX | Sandoz Pty Ltd | 60 075 449 553 |
IB | Apotex Pty Ltd | 52 096 916 148 |
IE | BeiGene AUS Pty Ltd | 23 164 802 037 |
IL | iNova Pharmaceuticals (Australia) Pty Limited | 13 617 871 539 |
IM | iNova Pharmaceuticals (Australia) Pty Limited | 13 617 871 539 |
IO | BioMarin Pharmaceutical Australia Pty Ltd | 69 159 743 496 |
IQ | Alcon Laboratories (Australia) Pty Ltd | 88 000 740 830 |
IR | Indivior Pty Ltd | 22 169 280 102 |
IS | Ipsen Pty Ltd | 47 095 036 909 |
IT | InterPharma Pty Ltd | 19 099 877 899 |
IU | AUPHARMA PTY LTD | 84 132 146 313 |
IX | Clinect Pty Ltd | 76 150 558 473 |
IY | Clinect Pty Ltd | 76 150 558 473 |
JA | JAZZ PHARMACEUTICALS ANZ PTY LTD | 83 643 560 534 |
JC | Janssen-Cilag Pty Ltd | 47 000 129 975 |
JM | Glenmark Pharmaceuticals (Australia) Pty Ltd | 23 116 922 500 |
JO | Juno Pharmaceuticals Pty Ltd | 55 156 303 650 |
JT | Johnson & Johnson Pacific Pty Limited | 73 001 121 446 |
JU | Juno Pharmaceuticals Pty Ltd | 55 156 303 650 |
JX | Juno Pharmaceuticals Pty Ltd | 55 156 303 650 |
JZ | Juniper Biologics Pty Ltd | 97 655 479 897 |
KO | KYOWA KIRIN AUSTRALIA PTY LTD | 47 631 934 453 |
KP | Eli Lilly Australia Pty Ltd | 39 000 233 992 |
KQ | PHERO PHARMA PTY LTD | 96 673 730 231 |
KY | Key Pharmaceuticals Pty Ltd | 21 001 215 130 |
LG | Leo Pharma Pty Ltd | 72 147 880 617 |
LL | Astellas Pharma Australia Pty Ltd | 81 147 915 482 |
LM | Link Medical Products Pty Ltd | 73 010 971 516 |
LN | Aspen Pharmacare Australia Pty Limited | 51 096 236 985 |
LO | Leo Pharma Pty Ltd | 72 147 880 617 |
LQ | Astellas Pharma Australia Pty Ltd | 81 147 915 482 |
LR | Cipla Australia Pty Ltd | 46 132 155 063 |
LT | Aspen Pharmacare Australia Pty Limited | 51 096 236 985 |
LU | Lundbeck Australia Pty Ltd | 86 070 094 290 |
LX | Lawley Pharmaceuticals Pty Ltd | 12 095 973 523 |
LY | Eli Lilly Australia Pty Ltd | 39 000 233 992 |
MF | Mundipharma Pty Limited | 87 081 322 509 |
MK | Merck Sharp & Dohme (Australia) Pty Ltd | 14 000 173 508 |
MQ | Alphapharm Pty Ltd | 93 002 359 739 |
MW | Biomed Aust Pty Limited | 67 080 084 377 |
NB | Nova Pharmaceuticals Australasia Pty Ltd | 87 104 838 440 |
NE | Norgine Pty. Ltd. | 78 005 022 882 |
NF | Novo Nordisk Pharmaceuticals Pty. Limited | 40 002 879 996 |
NG | NEON HEALTHCARE PTY LIMITED | 57 670 586 526 |
NI | Novo Nordisk Pharmaceuticals Pty. Limited | 40 002 879 996 |
NM | Novartis Pharmaceuticals Australia Pty Limited | 18 004 244 160 |
NO | Novo Nordisk Pharmaceuticals Pty. Limited | 40 002 879 996 |
NP | NICE-PAK PRODUCTS PTY. LTD. | 71 051 956 346 |
NQ | Takeda Pharmaceuticals Australia Pty. Ltd. | 71 095 610 870 |
NT | Nestle Australia Ltd | 77 000 011 316 |
NU | Nutricia Australia Pty Limited | 99 076 246 752 |
NV | Novartis Pharmaceuticals Australia Pty Limited | 18 004 244 160 |
OC | Accord Healthcare Pty. Ltd. | 49 110 502 513 |
OD | Accord Healthcare Pty. Ltd. | 49 110 502 513 |
OE | Omegapharm Pty Ltd | 86 128 078 151 |
OH | Orpharma Pty Ltd | 19 157 901 267 |
OJ | The Trustee for ORSPEC PHARMA UNIT TRUST | 15 634 980 417 |
ON | Orion Laboratories Pty. Ltd. | 56 009 293 136 |
OQ | Organon Pharma Pty Ltd | 54 637 107 512 |
OS | Otsuka Australia Pharmaceutical Pty. Ltd | 20 601 768 754 |
OU | Oraderm Pharmaceuticals Pty Ltd | 50 612 828 618 |
OV | Organon Pharma Pty Ltd | 54 637 107 512 |
OW | Arrow Pharma Pty Ltd | 35 605 909 920 |
OX | Orion Pharma (Aus) Pty Limited | 15 654 099 608 |
PB | Pharmaco (Australia) Limited | 89 113 383 501 |
PF | Pfizer Australia Pty Ltd | 50 008 422 348 |
PK | Fresenius Kabi Australia Pty Limited | 39 109 383 593 |
PP | Petrus Pharmaceuticals Pty Ltd | 21 108 884 126 |
QH | Cortex Health Pty Ltd | 17 144 062 386 |
QS | Sandoz Pty Ltd | 60 075 449 553 |
QY | Pro Pharmaceuticals Group Pty. Ltd. | 20 605 457 430 |
RA | Sun Pharma ANZ Pty Ltd | 17 110 871 826 |
RB | Bio Revive Pty Ltd | 58 097 360 417 |
RF | Arrow Pharma Pty Ltd | 35 605 909 920 |
RI | Dr Reddy's Laboratories (Australia) Pty Ltd | 16 120 092 408 |
RJ | Recordati Rare Diseases Australia Pty. Ltd. | 26 627 263 094 |
RN | Sun Pharma ANZ Pty Ltd | 17 110 871 826 |
RO | Roche Products Pty Ltd | 70 000 132 865 |
RQ | Reach Pharmaceuticals Pty Ltd | 25 623 897 183 |
RW | Arrow Pharma Pty Ltd | 35 605 909 920 |
RX | Servier Laboratories (Aust.) Pty. Ltd. | 54 004 838 500 |
RZ | Dr Reddy's Laboratories (Australia) Pty Ltd | 16 120 092 408 |
SA | SciGen (Australia) Pty Limited | 76 055 016 969 |
SB | Nutricia Australia Pty Limited | 99 076 246 752 |
SE | Servier Laboratories (Aust.) Pty. Ltd. | 54 004 838 500 |
SG | Merck Healthcare Pty Ltd | 72 006 900 830 |
SI | Sigma Company Limited | 44 004 132 923 |
SN | Smith & Nephew Pty Limited | 68 000 087 507 |
SW | sanofi-aventis Australia Pty Ltd | 31 008 558 807 |
SY | Bayer Australia Ltd | 22 000 138 714 |
SZ | Sandoz Pty Ltd | 60 075 449 553 |
TB | Teva Pharma Australia Pty Ltd | 41 169 715 664 |
TD | STADA Pharmaceuticals Australia Pty Limited | 73 154 966 944 |
TG | ANTENGENE (AUS) PTY. LTD. | 30 638 038 990 |
TJ | Taiho Pharma Oceania Pty Ltd | 97 675 212 530 |
TK | Takeda Pharmaceuticals Australia Pty. Ltd. | 71 095 610 870 |
TN | Medtas Pty Ltd | 72 644 270 860 |
TQ | Terumo BCT Australia Pty Limited | 87 130 046 865 |
TS | Specialised Therapeutics Australia Pty Ltd | 73 124 031 241 |
TT | Theramex Australia Pty Ltd | 37 623 186 845 |
TW | Apotex Pty Ltd | 52 096 916 148 |
TX | Apotex Pty Ltd | 52 096 916 148 |
TY | Apotex Pty Ltd | 52 096 916 148 |
UC | UCB Australia Proprietary Limited | 48 005 799 208 |
UJ | Upjohn Australia Pty Ltd | 50 629 389 911 |
UL | Bausch & Lomb (Australia) Pty Ltd | 88 000 222 408 |
UO | Bausch & Lomb (Australia) Pty Ltd | 88 000 222 408 |
UR | Camurus Pty Ltd | 79 627 784 605 |
VB | AbbVie Pty Ltd | 48 156 384 262 |
VE | AbbVie Pty Ltd | 48 156 384 262 |
VF | Vitaflo Australia Pty Limited | 82 097 161 254 |
VI | ViiV Healthcare Pty Ltd | 46 138 687 448 |
VL | Vifor Pharma Pty Limited | 87 086 114 043 |
VO | Avallon Pharmaceuticals Pty Limited | 63 126 872 848 |
VQ | Novartis Pharmaceuticals Australia Pty Limited | 18 004 244 160 |
VR | Vertex Pharmaceuticals (Australia) Pty. Ltd. | 34 160 157 157 |
VZ | Sanofi-aventis Healthcare Pty Ltd | 43 076 651 959 |
WA | sanofi-aventis Australia Pty Ltd | 31 008 558 807 |
WG | WAGNER PHARMACEUTICALS PTY LTD | 48 670 339 867 |
WM | MEDISON PHARMA AUSTRALIA PTY LIMITED | 19 659 723 403 |
WZ | Bridgewest Perth Pharma Pty Ltd | 21 663 385 411 |
XC | Southern Cross Pharma Pty Ltd | 47 094 447 677 |
XE | ACCELAGEN PTY LTD | 11 142 888 766 |
XH | MS Health Pty Ltd | 33 155 182 586 |
XI | Alexion Pharmaceuticals Australasia Pty Ltd | 59 132 343 036 |
XN | Southern XP Pty Ltd | 34 639 505 481 |
XO | Echo Therapeutics Pty Ltd | 92 628 298 699 |
XT | Arrotex Pharmaceuticals Pty Ltd | 30 605 552 234 |
XW | Arrotex Pharmaceuticals Pty Ltd | 30 605 552 234 |
XY | MAXX PHARMA PTY LTD | 33 629 622 224 |
YG | EUGIA PHARMA (AUSTRALIA) PTY LTD | 57 656 083 028 |
YN | Mayne Pharma International Pty Ltd | 88 007 870 984 |
YO | The Trustee for ORSPEC PHARMA UNIT TRUST | 15 634 980 417 |
YT | Mayne Products Pty Ltd | 59 140 866 379 |
ZB | Specialised Therapeutics Pm Pty Ltd | 50 617 311 083 |
ZE | Seekwell Pty Ltd | 91 624 401 618 |
ZL | Specialised Therapeutics Pharma Pty Ltd | 77 609 261 430 |
ZO | Swedish Orphan Biovitrum Pty Ltd | 14 645 396 532 |
ZS | Strides Pharma Science Pty Ltd | 44 635 036 734 |
ZU | Seekwell Pty Ltd | 91 624 401 618 |
[182] Schedule 4, Part 1, omit entry for Circumstances Code “C5820”
[183] Schedule 4, Part 1, omit entry for Circumstances Code “C5840”
[184] Schedule 4, Part 1, omit entry for Circumstances Code “C5841”
[185] Schedule 4, Part 1, omit entry for Circumstances Code “C5854”
[186] Schedule 4, Part 1, omit entry for Circumstances Code “C6429”
[187] Schedule 4, Part 1, omit entry for Circumstances Code “C13431”
[188] Schedule 4, Part 1, omit entry for Circumstances Code “C13436”
[189] Schedule 4, Part 1, omit entry for Circumstances Code “C13887”
[190] Schedule 4, Part 1, entry for Circumstances Code “C15269”
omit from the column headed “Listed Drug”: Saxagliptin with dapagliflozin
[191] Schedule 4, Part 1, entry for Circumstances Code “C15270”
omit from the column headed “Listed Drug”: Saxagliptin with dapagliflozin
[192] Schedule 4, Part 1, omit entry for Circumstances Code “C16189”
[193] Schedule 4, Part 1, entry for Circumstances Code “C16226”
substitute:
C16226 | P16226 | CN16226 | Somatropin | Severe growth hormone deficiency Initial treatment of late onset growth hormone deficiency Must be treated by an endocrinologist. Patient must have onset of growth hormone deficiency secondary to organic hypothalamic or pituitary disease diagnosed at chronological age of 18 years or older; OR Patient must have onset of growth hormone deficiency diagnosed after skeletal maturity (bone age greater than or equal to 15.5 years in males or 13.5 years in females) and before chronological age of 18 years; AND Patient must have a diagnostic insulin tolerance test with maximum serum growth hormone (GH) less than 2.5 micrograms per litre; OR Patient must have a diagnostic arginine infusion test with maximum serum GH less than 0.4 micrograms per litre; OR Patient must have a diagnostic glucagon provocation test with maximum serum GH less than 3 micrograms per litre; OR Patient must have: (a) a chronological age of 18 years or older, (b) established hypothalamic-pituitary disease, (c) at least three documented pituitary hormone deficiencies, (d) an IGF-1 concentration lower than the sex- and age-specific lower limit of normal in a patient. The authority application must be in writing and must include: 1. Details of the proposed prescription; AND 2. A completed Severe Growth Hormone Deficiency supporting information form; AND 3. If applicable, results of the growth hormone simulation testing, including the date of testing, the type of test performed, the peak growth hormone concentration, and laboratory reference range for age/gender. | Compliance with Written Authority Required procedures |
[194] Schedule 4, Part 1, entry for Circumstances Code “C16242”
substitute:
C16242 | P16242 | CN16242 | Somatropin | Severe growth hormone deficiency Initial treatment of childhood onset growth hormone deficiency in a patient who has received PBS-subsidised treatment as a child Must be treated by an endocrinologist. Patient must have a documented childhood onset growth hormone deficiency due to a congenital, genetic or structural cause; AND Patient must have previously received PBS-subsidised treatment with this drug for this condition as a child. Patient must have a mature skeleton. Somatropin is not PBS-subsidised for patients with Prader-Willi syndrome aged 18 years or older without a documented childhood onset Growth Hormone Deficiency. The authority application must be in writing and must include: 1. Details of the proposed prescription; AND 2. A completed Severe Growth Hormone Deficiency supporting information form. | Compliance with Written Authority Required procedures |
[195] Schedule 4, Part 1, entry for Circumstances Code “C16243”
substitute:
C16243 | P16243 | CN16243 | Somatropin | Severe growth hormone deficiency Initial treatment of childhood onset growth hormone deficiency in a patient who has received non-PBS subsidised treatment as a child Must be treated by an endocrinologist. Patient must have a documented childhood onset growth hormone deficiency due to a congenital, genetic or structural cause; AND Patient must have previously received non-PBS subsidised treatment with this drug for this condition as a child; AND Patient must have current or historical evidence of an insulin tolerance test with maximum serum growth hormone (GH) less than 2.5 micrograms per litre; OR Patient must have current or historical evidence of an arginine infusion test with maximum serum GH less than 0.4 micrograms per litre; OR Patient must have current or historical evidence of a glucagon provocation test with maximum serum GH less than 3 micrograms per litre. Patient must have a mature skeleton. Somatropin is not PBS-subsidised for patients with Prader-Willi syndrome aged 18 years or older without a documented childhood onset Growth Hormone Deficiency. The authority application must be in writing and must include: 1. Details of the proposed prescription; AND 2. A completed Severe Growth Hormone Deficiency supporting information form; AND 3. Results of the growth hormone stimulation testing, including the date of testing, the type of test performed, the peak growth hormone concentration, and laboratory reference range for age/gender. | Compliance with Written Authority Required procedures |
[196] Schedule 4, Part 1, after entry for Circumstances Code “C16252”
insert:
C16261 | P16261 | CN16261 | Enoxaparin Labetalol Levothyroxine Metformin | For prescribing by certain health practitioners Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife who is each of: (a) sharing patient care with a medical practitioner for the current pregnancy episode, (b) continuing existing treatment with this drug that was initiated by a medical practitioner. | |
C16264 | P16264 | CN16264 | Pembrolizumab | Stage IV (metastatic) non-small cell lung cancer (NSCLC) Initial treatment - 6 weekly treatment regimen Patient must not have previously been treated for this condition in the metastatic setting; or The condition must have progressed after treatment with only one of (i) tepotinib, (ii) selpercatinib; AND Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer; AND Patient must have a WHO performance status of 0 or 1; AND The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material; AND The treatment must not exceed a total of 4 doses under this restriction. | Compliance with Authority Required procedures - Streamlined Authority Code 16264 |
C16269 | P16269 | CN16269 | Hydroxocobalamin | Anaemias associated with vitamin B12 deficiency Patient must have had a gastrectomy; AND The treatment must be for prophylaxis; Patient must identify as Aboriginal or Torres Strait Islander; Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner. | |
C16270 | P16270 | CN16270 | Selpercatinib | Locally advanced or metastatic non-small cell lung cancer The condition must have evidence of rearranged during transfection (RET) gene fusion in tumour material - this evidence has been obtained prior to commencing treatment with this drug; AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of no higher than 2 at treatment initiation; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND Patient must be initiating treatment with this drug. or Patient must be continuing treatment with this drug, with an absence of further disease progression while being treated with this drug. Medical practitioners must prescribe the appropriate quantities of appropriate strength(s) to provide sufficient drug, based on the weight of the patient, adequate for 4 weeks per dispensing, according to the specified dosage in the approved Therapeutic Goods Administration (TGA) Product Information (PI). A separate authority prescription form must be completed for each strength requested. | Compliance with Authority Required procedures - Streamlined Authority Code 16270 |
C16273 | P16273 | CN16273 | Methyldopa | Hypertension Patient must be pregnant; Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, an endorsed midwife who is each of: (a) sharing patient care with a medical practitioner for the current pregnancy episode, (b) continuing existing treatment with this drug that was initiated by a medical practitioner. | Compliance with Authority Required procedures |
C16274 | P16274 | CN16274 | Methylphenidate | Attention deficit hyperactivity disorder Patient must have demonstrated a response to immediate-release methylphenidate hydrochloride with no emergence of serious adverse events; AND Patient must require continuous coverage over 12 hours; AND The treatment must not exceed a maximum daily dose of 72 mg of PBS-subsidised treatment with this drug; Patient must be or have been diagnosed between the ages of 6 and 18 years inclusive. | Compliance with Authority Required procedures |
C16276 | P16276 | CN16276 | Oxycodone Tramadol | Severe pain The treatment must be for short term therapy of acute severe pain; AND Patient must have had or would have inadequate pain management with maximum tolerated doses of non-opioid analgesics; or Patient must be unable to use non-opioid analgesics due to contraindications or intolerance; AND Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife who is sharing the post-operative care of the patient with a medical practitioner. | |
C16279 | P16279 | CN16279 | Temazepam | For prescribing by certain health practitioners Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner. | |
C16280 | P16280 | CN16280 | Pembrolizumab | Stage IV (metastatic) non-small cell lung cancer (NSCLC) Initial treatment - 3 weekly treatment regimen Patient must not have previously been treated for this condition in the metastatic setting; or The condition must have progressed after treatment with only one of (i) tepotinib, (ii) selpercatinib; AND Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer; AND Patient must have a WHO performance status of 0 or 1; AND The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material; AND The treatment must not exceed a total of 7 doses under this restriction. | Compliance with Authority Required procedures - Streamlined Authority Code 16280 |
C16282 | P16282 | CN16282 | Selpercatinib | Locally advanced or metastatic non-small cell lung cancer The condition must have evidence of rearranged during transfection (RET) gene fusion in tumour material - this evidence has been obtained prior to commencing treatment with this drug; AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of no higher than 2 at treatment initiation; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND Patient must be initiating treatment with this drug. or Patient must be continuing treatment with this drug, with an absence of further disease progression while being treated with this drug. Medical practitioners must prescribe the appropriate quantities of appropriate strength(s) to provide sufficient drug, based on the weight of the patient, adequate for 4 weeks per dispensing, according to the specified dosage in the approved Therapeutic Goods Administration (TGA) Product Information (PI). A separate authority prescription form must be completed for each strength requested. Medical practitioners may prescribe selpercatinib 80 mg with a quantity of up to 56 units where the dose does not exceed 120 mg twice daily (i.e., in combination with selpercatinib 40 mg). Selpercatinib 80 mg with a quantity of 112 units must be prescribed only where the dose is 160 mg twice daily to provide 28 days of treatment per dispensing. Prescribers should refer to the TGA PI for dosing and dose adjustments regimens. | Compliance with Authority Required procedures - Streamlined Authority Code 16282 |
C16285 | P16285 | CN16285 | Saxagliptin with dapagliflozin | Diabetes mellitus type 2 The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be in combination with at least metformin; AND The condition must be inadequately responsive to dual therapy consisting of metformin with either: a DDP-4 inhibitor, an SGLT2 inhibitor; AND Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor, another DPP4 inhibitor. | Compliance with Authority Required procedures |
C16288 | P16288 | CN16288 | Hydroxocobalamin | Pernicious anaemia Patient must identify as Aboriginal or Torres Strait Islander; Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner. | |
C16289 | P16289 | CN16289 | Hydroxocobalamin | Proven vitamin B12 deficiencies other than pernicious anaemia Patient must identify as Aboriginal or Torres Strait Islander; Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner, (iii) an endorsed midwife where patient care is being shared with a medical practitioner. | |
C16290 | P16290 | CN16290 | Saxagliptin with dapagliflozin | Diabetes mellitus type 2 The treatment must be in combination with at least metformin; AND The condition must be inadequately responsive to dual therapy consisting of metformin with either: a DDP-4 inhibitor, an SGLT2 inhibitor; AND Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor, another DPP4 inhibitor. | Compliance with Authority Required procedures |
[197] Schedule 5, entry for Abiraterone [GRP-29273]
insert as the first entry in the column headed “Brand”: Abiraterone Sandoz
[198] Schedule 5, entry for Abiraterone [GRP-29283]
insert as the first entry in the column headed “Brand”: Abiraterone Sandoz
[199] Schedule 5, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe
omit from the column headed “Brand”: Adalicip
[200] Schedule 5, omit entries for Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides
[201] Schedule 5, entry for Amlodipine [GRP-19809]
substitute:
Amlodipine | GRP-19809 | Tablet 10 mg (as besilate) | Oral | Amlo 10
Amlodipine APOTEX
Amlodipine GH
Amlodipine Sandoz
AMLODIPINE-WGR
APO-Amlodipine
APX-AMLODIPINE
Blooms Amlodipine
Blooms the Chemist Amlodipine
Nordip
Norvasc
NOUMED AMLODIPINE
Pharmacor Amlodipine |
[202] Schedule 5, after entry for Calcipotriol with betamethasone
insert:
Calcipotriol with betamethasone | GRP-29366 | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | Application | Enstilar
Klarvanta |
[203] Schedule 5, after entry for Dabigatran etexilate [GRP-28127]
insert:
Dapsone | GRP-29364 | Tablet 100 mg | Oral | DAPSOMED
Link Medical Products Pty Ltd |
[204] Schedule 5, entries for Estradiol
substitute:
Estradiol | GRP-27217 | Pessary (modified release) 10 micrograms (as hemihydrate) | Vaginal | Estro-Pess
Vagifem Low |
Estradiol | GRP-28649 | Transdermal patches 585 micrograms, 8 | Transdermal | Estradiol Transdermal System (Sandoz, USA)
Estradot 37.5 |
Estradiol | GRP-28651 | Transdermal patches 1.17 mg, 8 | Transdermal | Estradiol Transdermal System (Sandoz, USA)
Estradot 75 |
Estradiol | GRP-28652 | Transdermal patches 1.56 mg, 8 | Transdermal | Estradiol Transdermal System (Sandoz, USA)
Estradot 100 |
Estradiol | GRP-29372 | Transdermal patches 780 micrograms, 24 (S19A) | Transdermal | Estramon (Germany, Sandoz)
Estramon 50 (Germany) |
Estradiol | GRP-29376 | Transdermal patches 1.17 mg, 24 (S19A) | Transdermal | Estramon (Germany, Sandoz)
Estramon 75 (Germany) |
[205] Schedule 5, entries for Fenofibrate
substitute:
Fenofibrate | GRP-20716 | Tablet 145 mg | Oral | APO-Fenofibrate
BTC Fenofibrate
Fenocol
Fenofibrate Cipla
Fenofibrate Lupin
FENOFIBRATE RBX
Fenofibrate Sandoz
Fenofibrate Viatris
FENOFIBRATE-WGR
Lipidil |
Fenofibrate | GRP-20725 | Tablet 48 mg | Oral | APO-Fenofibrate
Fenofibrate Cipla
Fenofibrate Lupin
FENOFIBRATE RBX
Fenofibrate Viatris
FENOFIBRATE-WGR
Lipidil |
[206] Schedule 5, entry for Ganirelix
insert as the first entry in the column headed “Brand”: ARX Ganirelix
[207] Schedule 5, after entry for Macrogol 3350
insert:
Maraviroc | GRP-29369 | Tablet 300 mg | Oral | Celsentri
Maraviroc Waymade |
Maraviroc | GRP-29377 | Tablet 150 mg | Oral | Celsentri
Maraviroc Waymade |
[208] Schedule 5, entry for Mirtazapine [GRP-19763]
omit from the column headed “Brand”: NOUMED MIRTAZAPINE
[209] Schedule 5, omit entries for Niraparib
[210] Schedule 5, entry for Pirfenidone [GRP-27890]
insert as the first entry in the column headed “Brand”: ARX-Pirfenidone
[211] Schedule 5, entry for Pirfenidone [GRP-27892]
omit from the column headed “Form”: Tablet 801mg substitute: Tablet 801 mg
[212] Schedule 5, entries for Rivaroxaban
substitute:
Rivaroxaban | GRP-29154 | Tablet 2.5 mg | Oral | Rivaroxaban-Teva
RIVOXA
Xarelto |
Rivaroxaban | GRP-29164 | Tablet 20 mg | Oral | ARX-Rivaroxaban 20
iXarola
Rivaroxaban Dr.Reddy's
Rivaroxaban Sandoz
Rivaroxaban-Teva
Rivoxa
Xarelto |
Rivaroxaban | GRP-29169 | Tablet 10 mg | Oral | ARX-Rivaroxaban 10
iXarola
Rivaroxaban Dr.Reddy's
Rivaroxaban Sandoz
Rivaroxaban-Teva
Rivoxa
Xarelto |
Rivaroxaban | GRP-29173 | Tablet 15 mg | Oral | ARX-Rivaroxaban 15
iXarola
Rivaroxaban Dr.Reddy's
Rivaroxaban Sandoz
Rivaroxaban-Teva
Rivoxa
Xarelto |
[213] Schedule 5, entry for Telmisartan [GRP-19604]
omit from the column headed “Brand”: NOUMED TELMISARTAN
[214] Schedule 5, entry for Tenofovir in the form Tablet containing tenofovir disoproxil maleate 300 mg
omit from the column headed “Brand”: Tenofovir Disoproxil Mylan
[215] Schedule 5, after entry for Tetrabenazine
insert:
Ticagrelor | GRP-29370 | Tablet 90 mg | Oral | ARX-TICAGRELOR
Brilinta
TICALOR |
